143 related articles for article (PubMed ID: 11867028)
1. The Holy Grail: immune control of human herpes simplex virus infection and disease.
Cunningham AL; Mikloska Z
Herpes; 2001 Mar; 8 Suppl 1():6A-10A. PubMed ID: 11867028
[TBL] [Abstract][Full Text] [Related]
2. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
[TBL] [Abstract][Full Text] [Related]
3. Development of prophylactic vaccines for genital and neonatal herpes.
Jones CA; Cunningham AL
Expert Rev Vaccines; 2003 Aug; 2(4):541-9. PubMed ID: 14711338
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
[TBL] [Abstract][Full Text] [Related]
5. [Herpes simplex virus vaccine studies: from past to present].
Us D
Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
[TBL] [Abstract][Full Text] [Related]
6. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.
de Bruyn G; Vargas-Cortez M; Warren T; Tyring SK; Fife KH; Lalezari J; Brady RC; Shahmanesh M; Kinghorn G; Beutner KR; Patel R; Drehobl MA; Horner P; Kurtz TO; McDermott S; Wald A; Corey L
Vaccine; 2006 Feb; 24(7):914-20. PubMed ID: 16213066
[TBL] [Abstract][Full Text] [Related]
8. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
Quenelle DC; Collins DJ; Marciani DJ; Kern ER
Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
[TBL] [Abstract][Full Text] [Related]
9. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice.
Jazayeri M; Soleimanjahi H; Fotouhi F; Pakravan N
Comp Immunol Microbiol Infect Dis; 2009 Sep; 32(5):453-61. PubMed ID: 18571235
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
Stanberry LR
Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
[TBL] [Abstract][Full Text] [Related]
11. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes.
Macmillan L; Ifere GO; He Q; Igietseme JU; Kellar KL; Okenu DM; Eko FO
FEMS Immunol Med Microbiol; 2007 Feb; 49(1):46-55. PubMed ID: 17094789
[TBL] [Abstract][Full Text] [Related]
12. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
Tengvall S; O'Hagan D; Harandi AM
Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.
Bernstein DI; Aoki FY; Tyring SK; Stanberry LR; St-Pierre C; Shafran SD; Leroux-Roels G; Van Herck K; Bollaerts A; Dubin G;
Clin Infect Dis; 2005 May; 40(9):1271-81. PubMed ID: 15825029
[TBL] [Abstract][Full Text] [Related]
14. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.
Jones CA; Cunningham AL
Herpes; 2004 Apr; 11(1):12-7. PubMed ID: 15115632
[TBL] [Abstract][Full Text] [Related]
15. Vaccines for herpes simplex virus infections.
Koelle DM
Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
[TBL] [Abstract][Full Text] [Related]
16. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy.
Pepose JS; Keadle TL; Morrison LA
Am J Ophthalmol; 2006 Mar; 141(3):547-557. PubMed ID: 16490506
[TBL] [Abstract][Full Text] [Related]
17. An update on short-course episodic and prevention therapies for herpes genitalis.
Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
[TBL] [Abstract][Full Text] [Related]
18. Immunology. Painful failure of promising genital herpes vaccine.
Cohen J
Science; 2010 Oct; 330(6002):304. PubMed ID: 20947733
[No Abstract] [Full Text] [Related]
19. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice.
Tengvall S; Josefsson A; Holmgren J; Harandi AM
J Reprod Immunol; 2005 Dec; 68(1-2):53-69. PubMed ID: 16229896
[TBL] [Abstract][Full Text] [Related]
20. The cycle of human herpes simplex virus infection: virus transport and immune control.
Cunningham AL; Diefenbach RJ; Miranda-Saksena M; Bosnjak L; Kim M; Jones C; Douglas MW
J Infect Dis; 2006 Sep; 194 Suppl 1():S11-8. PubMed ID: 16921466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]